Handelsbanken Fonder AB lifted its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 7.1% during the fourth quarter, HoldingsChannel reports. The firm owned 25,515 shares of the biotechnology company’s stock after purchasing an additional 1,700 shares during the quarter. Handelsbanken Fonder AB’s holdings in Sarepta Therapeutics were worth $3,102,000 as of its most recent SEC filing.
A number of other institutional investors have also made changes to their positions in SRPT. Manchester Capital Management LLC lifted its position in shares of Sarepta Therapeutics by 86.6% during the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 110 shares in the last quarter. MassMutual Private Wealth & Trust FSB lifted its position in shares of Sarepta Therapeutics by 169.6% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 156 shares in the last quarter. Sunbelt Securities Inc. lifted its position in shares of Sarepta Therapeutics by 446.2% during the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 232 shares in the last quarter. Huntington National Bank lifted its position in shares of Sarepta Therapeutics by 150.9% during the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 175 shares in the last quarter. Finally, Newbridge Financial Services Group Inc. acquired a new stake in Sarepta Therapeutics in the fourth quarter valued at $36,000. 86.68% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
SRPT has been the topic of several recent analyst reports. Evercore ISI cut their price target on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a report on Thursday, November 7th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Sarepta Therapeutics in a report on Tuesday, February 11th. They issued a “hold” rating and a $136.00 price target on the stock. Piper Sandler cut their price target on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating on the stock in a report on Wednesday, November 27th. Guggenheim upped their price target on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Finally, Robert W. Baird cut their price target on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating on the stock in a report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $176.77.
Sarepta Therapeutics Stock Down 0.7 %
Sarepta Therapeutics stock opened at $105.56 on Tuesday. The company has a 50-day simple moving average of $117.11 and a 200-day simple moving average of $123.14. The firm has a market capitalization of $10.08 billion, a P/E ratio of 84.45 and a beta of 0.75. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. Sarepta Therapeutics, Inc. has a one year low of $101.15 and a one year high of $173.25.
Insider Transactions at Sarepta Therapeutics
In related news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the completion of the transaction, the director now owns 22,840 shares in the company, valued at $2,851,345.60. This represents a 31.49 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the completion of the transaction, the director now owns 5,880 shares of the company’s stock, valued at $738,234. This represents a 21.77 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.70% of the company’s stock.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.
Featured Articles
- Five stocks we like better than Sarepta Therapeutics
- Do ETFs Pay Dividends? What You Need to Know
- Finding Hidden Gems: Unconventional Penny Stock Investing
- There Are Different Types of Stock To Invest In
- Price Targets on NVIDIA Rise in Front of Earnings
- 3 Best Fintech Stocks for a Portfolio Boost
- Archer Aviation Stock Skids: Mistaking Progress for Bad News?
Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.